Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACH: Pomalidomide for HIV Control During Analytical Treatment Interruption
NCT06660498Phase 2Active, not recruiting
- Sponsor
- Aarhus University
- Start
- May 2025
- Primary completion
- Mar 2027
- Modality
- Molecular Glues
- Countries
- 2
01
Overview
Phase 2, randomised trial in human immunodeficiency virus infection (HIV) comparing Pomalidomide with Placebo (2 arms). Primary endpoints: Time from ART cessation until meeting ART restart criteria and Number of treatment-emergent adverse events of grade 3 or higher related to study treatment. Started May 2025; status: active, not recruiting.
02
Drugs
pomalidomide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06660498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660498.